Fig. 5From: Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trialsAny grade of adverse events of patients with advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma treated with Zolbetuximab plus chemotherapy versus chemotherapy alone. (A) Nausea. (B) Vomiting. (C) Decrease appetite. (D) Oedema peripheralBack to article page